Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Neoplasms 8Neoplasms by Site 4Digestive System Neoplasms 4Pancreatic Neoplasms 3Neoplasms, Glandular and Epithelial 3Digestive System Diseases 3Colorectal Neoplasms 3Pancreatic Diseases 2Neoplasms by Histologic Type 2Endocrine Gland Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Adenocarcinoma 2Thymus Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Previously Treated Metastatic Colorectal Cancer 1Pancreatic cancer, adult 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Intestinal Neoplasms 1Intestinal Diseases 1

Interventions

Azacitidine 14venetoclax 10AP 1903 reagent 7Rituximab 6Dexamethasone 6Itraconazole 5Cytarabine 5Bortezomib 5fludarabine 4fedratinib 4belinostat 4Nivolumab 4Lenalidomide 4Imatinib Mesylate 4Daunorubicin 4ARQ531 4pomalidomide 3ibrutinib 3daratumumab 3cc-486 3angiotensin I (1-7) 3Standard of Care 3GSK2110183 3Cyclophosphamide 3zanubrutinib 2tosedostat 2tazemetostat 2tanespimycin 2talquetamab 2tafasitamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Neoplasms × napabucasin × Clear all
NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Sumitomo Pharma America, Inc.

Phase 1 Completed
15 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡